CoChat
Sign Up
Cited by 332

The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.

Tuberous sclerosis: a GAP at the crossroads of multiple signaling pathways

Kwiatkowski, David J., Manning, Brendan D.·2005·Human Molecular Genetics
DOI 10.1093/hmg/ddi260
Open this paper in CoChat — free account

Abstract

Tuberous sclerosis complex (TSC) is an autosomal dominant disorder that is characterized by benign tumors (hamartomas and hamartias) involving multiple organ systems, due to inactivating mutations in TSC1 or TSC2. Here, we review recent advances in our understanding of the growth and signaling functions of the TSC1 and TSC2 proteins. Led by seminal studies in Drosophila, the TSC1/TSC2 complex has been positioned in an ancestrally conserved signaling pathway that regulates cell growth. TSC1/TSC2 receives inputs from at least three major signaling pathways in the form of kinase-mediated phosphorylation events that regulate its function as a GTPase activating protein (GAP): the PI3K-Akt pathway, the ERK1/2-RSK1 pathway and the LKB1-AMPK pathway. TSC1/TSC2 functions as a GAP towards Rheb, which is a major regulator of the mammalian target of rapamycin (mTOR). In the absence of either TSC1 or TSC2, high levels of Rheb-GTP lead to constitutive activation of mTOR-raptor signaling, thereby leading to enhanced and deregulated protein synthesis and cell growth. As a specific inhibitor of mTOR, rapamycin has therapeutic potential for the treatment of TSC hamartomas.

Overview

Integrity signals

Registry

Crossref · 10.1093/hmg/ddi260

Cites

6 of 6 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Tuberin is a GTPase-activating protein that regulates the small G protein Rheb, a strong activator of mTOR.

    “Tuberin is a GTPase-activating protein that regulates the small G protein Rheb, a strong activator of mTOR[17](#R17).”

    From Reversal of learning deficits in a Tsc2+/− mouse model of tuberous sclerosis (2008) · cites this paper as [17]

Citations

Cites

Flagged first, then by citations

Research works printed but not linked: 88

  1. Gomez, M., Sampson, J. and Whittemore, V. (eds) (1999) The Tuberous Sclerosis Complex, 3rd edn. Oxford University Press, Oxford, England. · DOI
  2. Curatolo, P. (2003) Tuberous Sclerosis Complex: from Basic Science to Clinical Phenotypes. Mac Keith Press, Cambridge.
  3. Roach, E.S., Gomez, M.R. and Northrup, H. (1998) Tuberous sclerosis complex consensus conference: revised clinical diagnostic criteria. J. Child Neurol., 13, 624–628. · DOI
  4. Al-Saleem, T., Wessner, L.L., Scheithauer, B.W., Patterson, K., Roach, E.S., Dreyer, S.J., Fujikawa, K., Bjornsson, J., Bernstein, J. and Henske, E.P. (1998) Malignant tumors of the kidney, brain, and soft tissues in children and young adults with the tuberous sclerosis complex. Cancer, 83, 2208–2216. · DOI
  5. Crino, P.B. (2004) Molecular pathogenesis of tuber formation in tuberous sclerosis complex. J. Child Neurol., 19, 716–725. · DOI
  6. DiMario, F.J., Jr. (2004) Brain abnormalities in tuberous sclerosis complex. J. Child Neurol., 19, 650–657. · DOI
  7. Goodman, M., Lamm, S.H., Engel, A., Shepherd, C.W., Houser, O.W. and Gomez, M.R. (1997) Cortical tuber count: a biomarker indicating neurologic severity of tuberous sclerosis complex. J. Child Neurol., 12, 85–90. · DOI
  8. Prather, P. and de Vries, P.J. (2004) Behavioral and cognitive aspects of tuberous sclerosis complex. J. Child Neurol., 19, 666–674. · DOI
  9. Webb, D.W., Clarke, A., Fryer, A. and Osborne, J.P. (1996) The cutaneous features of tuberous sclerosis: a population study. Br. J. Dermatol., 135, 1–5. · DOI
  10. Ewalt, D.H., Sheffield, E., Sparagana, S.P., Delgado, M.R. and Roach, E.S. (1998) Renal lesion growth in children with tuberous sclerosis complex. J. Urol., 160, 141–145. · DOI
  11. Moss, J., Avila, N.A., Barnes, P.M., Litzenberger, R.A., Bechtle, J., Brooks, P.G., Hedin, C.J., Hunsberger, S. and Kristof, A.S. (2001) Prevalence and clinical characteristics of lymphangioleiomyomatosis (LAM) in patients with tuberous sclerosis complex. Am. J. Respir. Crit. Care Med., 164, 669–671. · DOI
  12. Urban, T., Lazor, R., Lacronique, J., Murris, M., Labrune, S., Valeyre, D. and Cordier, J.F. (1999) Pulmonary lymphangioleiomyomatosis. A study of 69 patients. Groupe d'Etudes et de Recherche sur les Maladies ‘Orphelines’ Pulmonaires (GERM‘O'P). Medicine (Baltimore), 78, 321–337. · DOI
  13. Cheadle, J.P., Reeve, M.P., Sampson, J.R. and Kwiatkowski, D.J. (2000) Molecular genetic advances in tuberous sclerosis. Hum. Genet., 107, 97–114. · DOI
  14. Dabora, S.L., Jozwiak, S., Franz, D.N., Roberts, P.S., Nieto, A., Chung, J., Choy, Y.S., Reeve, M.P., Thiele, E., Egelhoff, J.C. et al. (2001) Mutational analysis in a cohort of 224 tuberous sclerosis patients indicates increased severity of TSC2, compared with TSC1, disease in multiple organs. Am. J. Hum. Genet., 68, 64–80. · DOI
  15. Jones, A.C., Shyamsundar, M.M., Thomas, M.W., Maynard, J., Idziaszczyk, S., Tomkins, S., Sampson, J.R. and Cheadle, J.P. (1999) Comprehensive mutation analysis of TSC1 and TSC2-and phenotypic correlations in 150 families with tuberous sclerosis. Am. J. Hum. Genet., 64, 1305–1315. · DOI
  16. Sancak, O., Nellist, M., Goedbloed, M., Elfferich, P., Wouters, C., Maat-Kievit, A., Zonnenberg, B., Verhoef, S., Halley, D. and van den Ouweland, A. (2005) Mutational analysis of the TSC1 and TSC2 genes in a diagnostic setting: genotype–phenotype correlations and comparison of diagnostic DNA techniques in tuberous sclerosis complex. Eur. J. Hum. Genet., 13, 731–741. · DOI
  17. O'Connor, S.E., Kwiatkowski, D.J., Roberts, P.S., Wollmann, R.L. and Huttenlocher, P.R. (2003) A family with seizures and minor features of tuberous sclerosis and a novel TSC2 mutation. Neurology, 61, 409–412. · DOI
  18. Khare, L., Strizheva, G.D., Bailey, J.N., Au, K.S., Northrup, H., Smith, M., Smalley, S.L. and Henske, E.P. (2001) A novel missense mutation in the GTPase activating protein homology region of TSC2 in two large families with tuberous sclerosis complex. J. Med. Genet., 38, 347–349. · DOI
  19. Au, K.S., Hebert, A.A., Roach, E.S. and Northrup, H. (1999) Complete inactivation of the TSC2 gene leads to formation of hamartomas. Am. J. Hum. Genet., 65, 1790–1795. · DOI
  20. Carbonara, C., Longa, L., Grosso, E., Mazzucco, G., Borrone, C., Garre, M.L., Brisigotti, M., Filippi, G., Scabar, A., Giannotti, A. et al. (1996) Apparent preferential loss of heterozygosity at TSC2 over TSC1 chromosomal region in tuberous sclerosis hamartomas. Genes Chromosomes Cancer, 15, 18–25. · DOI
  21. Green, A.J., Smith, M. and Yates, J.R. (1994) Loss of heterozygosity on chromosome 16p13.3 in hamartomas from tuberous sclerosis patients. Nat. Genet., 6, 193–196. · DOI
  22. Niida, Y., Stemmer-Rachamimov, A.O., Logrip, M., Tapon, D., Perez, R., Kwiatkowski, D.J., Sims, K., MacCollin, M., Louis, D.N. and Ramesh, V. (2001) Survey of somatic mutations in tuberous sclerosis complex (TSC) hamartomas suggests different genetic mechanisms for pathogenesis of TSC lesions. Am. J. Hum. Genet., 69, 493–503. · DOI
  23. Tucker, T. and Friedman, J.M. (2002) Pathogenesis of hereditary tumors: beyond the ‘two-hit’ hypothesis. Clin. Genet., 62, 345–357. · DOI
  24. Han, S., Santos, T.M., Puga, A., Roy, J., Thiele, E.A., McCollin, M., Stemmer-Rachamimov, A. and Ramesh, V. (2004) Phosphorylation of tuberin as a novel mechanism for somatic inactivation of the tuberous sclerosis complex proteins in brain lesions. Cancer Res., 64, 812–816. · DOI
  25. Chan, J.A., Zhang, H., Roberts, P.S., Jozwiak, S., Wieslawa, G., Lewin-Kowalik, J., Kotulska, K. and Kwiatkowski, D.J. (2004) Pathogenesis of tuberous sclerosis subependymal giant cell astrocytomas: biallelic inactivation of TSC1 or TSC2 leads to mTOR activation. J. Neuropath. Exp. Neurol., 63, 1236–1242. · DOI
  26. The European Chromosome 16 Tuberous Sclerosis Consortium. (1993) Identification and characterization of the tuberous sclerosis gene on chromosome 16. Cell, 75, 1305–1315. · DOI · Paper page
  27. van Slegtenhorst, M., de Hoogt, R., Hermans, C., Nellist, M., Janssen, B., Verhoef, S., Lindhout, D., van den Ouweland, A., Halley, D., Young, J. et al. (1997) Identification of the tuberous sclerosis gene TSC1 on chromosome 9q34. Science, 277, 805–808. · DOI · Paper page
  28. van Slegtenhorst, M., Nellist, M., Nagelkerken, B., Cheadle, J., Snell, R., van den Ouweland, A., Reuser, A., Sampson, J., Halley, D. and van der Sluijs, P. (1998) Interaction between hamartin and tuberin, the TSC1 and TSC2 gene products. Hum. Mol. Genet., 7, 1053–1058. · DOI · Paper page
  29. Gao, X. and Pan, D. (2001) TSC1 and TSC2 tumor suppressors antagonize insulin signaling in cell growth. Genes Dev., 15, 1383–1392. · DOI
  30. Potter, C.J., Huang, H. and Xu, T. (2001) Drosophila Tsc1 functions with Tsc2 to antagonize insulin signaling in regulating cell growth, cell proliferation, and organ size. Cell, 105, 357–368. · DOI
  31. Tapon, N., Ito, N., Dickson, B.J., Treisman, J.E. and Hariharan, I.K. (2001) The Drosophila tuberous sclerosis complex gene homologs restrict cell growth and cell proliferation. Cell, 105, 345–355. · DOI
  32. Fingar, D.C. and Blenis, J. (2004) Target of rapamycin (TOR): an integrator of nutrient and growth factor signals and coordinator of cell growth and cell cycle progression. Oncogene, 23, 3151–3171. · DOI
  33. Nobukini, T. and Thomas, G. (2004) The mTOR/S6K signalling pathway: the role of the TSC1/2 tumour suppressor complex and the proto-oncogene Rheb. Novartis Found. Symp., 262, 148–154. · DOI
  34. Pan, D., Dong, J., Zhang, Y. and Gao, X. (2004) Tuberous sclerosis complex: from Drosophila to human disease. Trends Cell Biol., 14, 78–85. · DOI
  35. Findlay, G.M., Harrington, L.S. and Lamb, R.F. (2005) TSC1-2 tumour suppressor and regulation of mTOR signalling: linking cell growth and proliferation? Curr. Opin. Genet. Dev., 15, 69–76. · DOI
  36. Hardie, D.G. (2005) New roles for the LKB1–>AMPK pathway. Curr. Opin. Cell Biol., 17, 167–173. · DOI
  37. Inoki, K., Corradetti, M.N. and Guan, K.L. (2005) Dysregulation of the TSC-mTOR pathway in human disease. Nat. Genet., 37, 19–24. · DOI
  38. Inoki, K., Ouyang, H., Li, Y. and Guan, K.L. (2005) Signaling by target of rapamycin proteins in cell growth control. Microbiol. Mol. Biol. Rev., 69, 79–100. · DOI
  39. Manning, B.D. (2004) Balancing Akt with S6K: implications for both metabolic diseases and tumorigenesis. J. Cell Biol., 167, 399–403. · DOI
  40. Vanhaesebroeck, B. and Alessi, D.R. (2000) The PI3K–PDK1 connection: more than just a road to PKB. Biochem. J., 346, 561–576. · DOI
  41. Alessi, D.R., Deak, M., Casamayor, A., Caudwell, F.B., Morrice, N., Norman, D.G., Gaffney, P., Reese, C.B., MacDougall, C.N., Harbison, D. et al. (1997) 3-Phosphoinositide-dependent protein kinase-1 (PDK1): structural and functional homology with the Drosophila DSTPK61 kinase. Curr. Biol., 7, 776–789. · DOI
  42. Downward, J. (2004) PI 3-kinase, Akt and cell survival. Semin. Cell Dev. Biol., 15, 177–182. · DOI
  43. Manning, B.D. and Cantley, L.C. (2003) United at last: the tuberous sclerosis complex gene products connect the phosphoinositide 3-kinase/Akt pathway to mammalian target of rapamycin (mTOR) signalling. Biochem. Soc. Trans., 31, 573–578. · DOI
  44. Saucedo, L.J., Gao, X., Chiarelli, D.A., Li, L., Pan, D. and Edgar, B.A. (2003) Rheb promotes cell growth as a component of the insulin/TOR signalling network. Nat. Cell Biol., 5, 566–571. · DOI
  45. Stocker, H., Radimerski, T., Schindelholz, B., Wittwer, F., Belawat, P., Daram, P., Breuer, S., Thomas, G. and Hafen, E. (2003) Rheb is an essential regulator of S6K in controlling cell growth in Drosophila. Nat. Cell Biol., 5, 559–565. · DOI
  46. Zhang, Y., Gao, X., Saucedo, L.J., Ru, B., Edgar, B.A. and Pan, D. (2003) Rheb is a direct target of the tuberous sclerosis tumour suppressor proteins. Nat. Cell Biol., 5, 578–581. · DOI
  47. Garami, A., Zwartkruis, F.J., Nobukuni, T., Joaquin, M., Roccio, M., Stocker, H., Kozma, S.C., Hafen, E., Bos, J.L. and Thomas, G. (2003) Insulin activation of Rheb, a mediator of mTOR/S6K/4E-BP signaling, is inhibited by TSC1 and 2. Mol. Cell, 11, 1457–1466. · DOI · Paper page
  48. Dan, H.C., Sun, M., Yang, L., Feldman, R.I., Sui, X.M., Yeung, R.S., Halley, D.J., Nicosia, S.V., Pledger, W.J. and Cheng, J.Q. (2002) PI3K/AKT pathway regulates TSC tumor suppressor complex by phosphorylation of tuberin. J. Biol. Chem., 277, 35364–35370. · DOI
  49. Inoki, K., Li, Y., Zhu, T., Wu, J. and Guan, K.L. (2002) TSC2 is phosphorylated and inhibited by Akt and suppresses mTOR signalling. Nat. Cell Biol., 4, 648–657. · DOI · Paper page
  50. Manning, B.D., Tee, A.R., Logsdon, M.N., Blenis, J. and Cantley, L.C. (2002) Identification of the tuberous sclerosis complex-2 tumor suppressor gene product tuberin as a target of the phosphoinositide 3-kinase/akt pathway. Mol. Cell, 10, 151–162. · DOI · Paper page
  51. Potter, C.J., Pedraza, L.G. and Xu, T. (2002) Akt regulates growth by directly phosphorylating Tsc2. Nat. Cell Biol., 4, 658–665. · DOI · Paper page
  52. Im, E., von Lintig, F.C., Chen, J., Zhuang, S., Qui, W., Chowdhury, S., Worley, P.F., Boss, G.R. and Pilz, R.B. (2002) Rheb is in a high activation state and inhibits B-Raf kinase in mammalian cells. Oncogene, 21, 6356–6365. · DOI
  53. Tee, A.R., Manning, B.D., Roux, P.P., Cantley, L.C. and Blenis, J. (2003) Tuberous sclerosis complex gene products, tuberin and hamartin, control mTOR signaling by acting as a GTPase-activating protein complex toward Rheb. Curr. Biol., 13, 1259–1268. · DOI · Paper page
  54. Martin, D.E. and Hall, M.N. (2005) The expanding TOR signaling network. Curr. Opin. Cell Biol., 17, 158–166. · DOI
  55. Tee, A.R. and Blenis, J. (2005) mTOR, translational control and human disease. Semin. Cell Dev. Biol., 16, 29–37. · DOI
  56. Hara, K., Maruki, Y., Long, X., Yoshino, K., Oshiro, N., Hidayat, S., Tokunaga, C., Avruch, J. and Yonezawa, K. (2002) Raptor, a binding partner of target of rapamycin (TOR), mediates TOR action. Cell, 110, 177–189. · DOI
  57. Kim, D.H., Sarbassov dos, D., Ali, S.M., King, J.E., Latek, R.R., Erdjument-Bromage, H., Tempst, P. and Sabatini, D.M. (2002) mTOR interacts with raptor to form a nutrient-sensitive complex that signals to the cell growth machinery. Cell, 110, 163–175. · DOI
  58. Kim, D.H., Sarbassov dos, D., Ali, S.M., Latek, R.R., Guntur, K.V., Erdjument-Bromage, H., Tempst, P. and Sabatini, D.M. (2003) GbetaL, a positive regulator of the rapamycin-sensitive pathway required for the nutrient-sensitive interaction between raptor and mTOR. Mol. Cell, 11, 895–904. · DOI
  59. Sarbassov, D.D., Ali, S.M., Kim, D.H., Guertin, D.A., Latek, R.R., Erdjument-Bromage, H., Tempst, P. and Sabatini, D.M. (2004) Rictor, a novel binding partner of mTOR, defines a rapamycin-insensitive and raptor-independent pathway that regulates the cytoskeleton. Curr. Biol., 14, 1296–1302. · DOI · Paper page
  60. Jacinto, E., Loewith, R., Schmidt, A., Lin, S., Ruegg, M.A., Hall, A. and Hall, M.N. (2004) Mammalian TOR complex 2 controls the actin cytoskeleton and is rapamycin insensitive. Nat. Cell Biol., 6, 1122–1128. · DOI
  61. Long, X., Lin, Y., Ortiz-Vega, S., Yonezawa, K. and Avruch, J. (2005) Rheb binds and regulates the mTOR kinase. Curr. Biol., 15, 702–713. · DOI · Paper page
  62. Hara, K., Yonezawa, K., Weng, Q.P., Kozlowski, M.T., Belham, C. and Avruch, J. (1998) Amino acid sufficiency and mTOR regulate p70 S6 kinase and eIF-4E BP1 through a common effector mechanism. J. Biol. Chem., 273, 14484–14494. · DOI
  63. Smith, E.M., Finn, S.G., Tee, A.R., Browne, G.J. and Proud, C.G. (2005) The tuberous sclerosis protein TSC2 is not required for the regulation of the mammalian target of rapamycin by amino acids and certain cellular stresses. J. Biol. Chem., 280, 18717–18727. · DOI
  64. Richardson, C.J., Broenstrup, M., Fingar, D.C., Julich, K., Ballif, B.A., Gygi, S. and Blenis, J. (2004) SKAR is a specific target of S6 kinase 1 in cell growth control. Curr. Biol., 14, 1540–1549. · DOI
  65. Raught, B., Peiretti, F., Gingras, A.C., Livingstone, M., Shahbazian, D., Mayeur, G.L., Polakiewicz, R.D., Sonenberg, N. and Hershey, J.W. (2004) Phosphorylation of eucaryotic translation initiation factor 4B Ser422 is modulated by S6 kinases. EMBO J., 23, 1761–1769. · DOI
  66. Lazaris-Karatzas, A., Montine, K.S. and Sonenberg, N. (1990) Malignant transformation by a eukaryotic initiation factor subunit that binds to mRNA 5′ cap. Nature, 345, 544–547. · DOI
  67. Wendel, H.G., De Stanchina, E., Fridman, J.S., Malina, A., Ray, S., Kogan, S., Cordon-Cardo, C., Pelletier, J. and Lowe, S.W. (2004) Survival signalling by Akt and eIF4E in oncogenesis and cancer therapy. Nature, 428, 332–337. · DOI
  68. Hawley, S.A., Boudeau, J., Reid, J.L., Mustard, K.J., Udd, L., Makela, T.P., Alessi, D.R. and Hardie, D.G. (2003) Complexes between the LKB1 tumor suppressor, STRAD alpha/beta and MO25 alpha/beta are upstream kinases in the AMP-activated protein kinase cascade. J. Biol., 2, 28. · DOI
  69. Inoki, K., Zhu, T. and Guan, K.L. (2003) TSC2 mediates cellular energy response to control cell growth and survival. Cell, 115, 577–590. · DOI · Paper page
  70. Shaw, R.J., Bardeesy, N., Manning, B.D., Lopez, L., Kosmatka, M., DePinho, R.A. and Cantley, L.C. (2004) The LKB1 tumor suppressor negatively regulates mTOR signaling. Cancer Cell, 6, 91–99. · DOI
  71. Corradetti, M.N., Inoki, K., Bardeesy, N., DePinho, R.A. and Guan, K.L. (2004) Regulation of the TSC pathway by LKB1: evidence of a molecular link between tuberous sclerosis complex and Peutz–Jeghers syndrome. Genes Dev., 18, 1533–1538. · DOI
  72. Roux, P.P., Ballif, B.A., Anjum, R., Gygi, S.P. and Blenis, J. (2004) Tumor-promoting phorbol esters and activated Ras inactivate the tuberous sclerosis tumor suppressor complex via p90 ribosomal S6 kinase. Proc. Natl Acad. Sci. USA, 101, 13489–13494. · DOI
  73. Ma, L., Chen, Z., Erdjument-Bromage, H., Tempst, P. and Pandolfi, P.P. (2005) Phosphorylation and functional inactivation of TSC2 by Erk implications for tuberous sclerosis and cancer pathogenesis. Cell, 121, 179–193. · DOI · Paper page
  74. Ballif, B.A., Roux, P.P., Gerber, S.A., MacKeigan, J.P., Blenis, J. and Gygi, S.P. (2005) Quantitative phosphorylation profiling of the ERK/p90 ribosomal S6 kinase-signaling cassette and its targets, the tuberous sclerosis tumor suppressors. Proc. Natl Acad. Sci. USA, 102, 667–672. · DOI
  75. Astrinidis, A., Senapedis, W., Coleman, T.R. and Henske, E.P. (2003) Cell cycle-regulated phosphorylation of hamartin, the product of the tuberous sclerosis complex 1 gene, by cyclin-dependent kinase 1/cyclin B. J. Biol. Chem., 278, 51372–51379. · DOI
  76. Reiling, J.H. and Hafen, E. (2004) The hypoxia-induced paralogs Scylla and Charybdis inhibit growth by down-regulating S6K activity upstream of TSC in Drosophila. Genes Dev., 18, 2879–2892. · DOI
  77. Brugarolas, J., Lei, K., Hurley, R.L., Manning, B.D., Reiling, J.H., Hafen, E., Witters, L.A., Ellisen, L.W. and Kaelin, W.G., Jr. (2004) Regulation of mTOR function in response to hypoxia by REDD1 and the TSC1/TSC2 tumor suppressor complex. Genes Dev., 18, 2893–2904. · DOI · Paper page
  78. Zhang, H., Cicchetti, G., Onda, H., Koon, H.B., Asrican, K., Bajraszewski, N., Vazquez, F., Carpenter, C.L. and Kwiatkowski, D.J. (2003) Loss of Tsc1/Tsc2 activates mTOR and disrupts PI3K-Akt signaling through downregulation of PDGFR. J. Clin. Invest., 112, 1223–1233. · DOI
  79. Nellist, M., Sancak, O., Goedbloed, M.A., Rohe, C., van Netten, D., Mayer, K., Tucker-Williams, A., van den Ouweland, A.M. and Halley, D.J. (2005) Distinct effects of single amino-acid changes to tuberin on the function of the tuberin–hamartin complex. Eur. J. Hum. Genet., 13, 59–68. · DOI
  80. El-Hashemite, N., Zhang, H., Henske, E.P. and Kwiatkowski, D.J. (2003) Mutation in TSC2 and activation of mammalian target of rapamycin signalling pathway in renal angiomyolipoma. Lancet, 361, 1348–1349. · DOI
  81. Goncharova, E.A., Goncharov, D.A., Eszterhas, A., Hunter, D.S., Glassberg, M.K., Yeung, R.S., Walker, C.L., Noonan, D., Kwiatkowski, D.J., Chou, M.M. et al. (2002) Tuberin regulates p70 S6 kinase activation and ribosomal protein S6 phosphorylation: a role for the TSC2 tumor suppressor gene in pulmonary lymphangioleiomyomatosis (LAM). J. Biol. Chem., 277, 30958–30967. · DOI
  82. Jaeschke, A., Hartkamp, J., Saitoh, M., Roworth, W., Nobukuni, T., Hodges, A., Sampson, J., Thomas, G. and Lamb, R. (2002) Tuberous sclerosis complex tumor suppressor-mediated S6 kinase inhibition by phosphatidylinositide-3-OH kinase is mTOR independent. J. Cell Biol., 159, 217–224. · DOI
  83. Kwiatkowski, D.J., Zhang, H., Bandura, J.L., Heiberger, K.M., Glogauer, M., el-Hashemite, N. and Onda, H. (2002) A mouse model of TSC1 reveals sex-dependent lethality from liver hemangiomas, and up-regulation of p70S6 kinase activity in Tsc1 null cells. Hum. Mol. Genet., 11, 525–534. · DOI
  84. Harrington, L.S., Findlay, G.M., Gray, A., Tolkacheva, T., Wigfield, S., Rebholz, H., Barnett, J., Leslie, N.R., Cheng, S., Shepherd, P.R. et al. (2004) The TSC1-2 tumor suppressor controls insulin-PI3K signaling via regulation of IRS proteins. J. Cell Biol., 166, 213–223. · DOI
  85. Shah, O.J., Wang, Z. and Hunter, T. (2004) Inappropriate activation of the TSC/Rheb/mTOR/S6K cassette induces IRS1/2 depletion, insulin resistance, and cell survival deficiencies. Curr. Biol., 14, 1650–1656. · DOI
  86. Manning, B.D., Logsdon, M.N., Lipovsky, A., Abbott, D., Kwiatkowski, D.J. and Cantley, L.C. (2005) Feedback inhibition of Akt signaling limits the growth of tumors lacking Tsc2. Genes Dev., in press. · DOI
  87. Kenerson, H., Dundon, T.A. and Yeung, R.S. (2004) Effects of rapamycin in the eker rat model of tuberous sclerosis complex. Pediatr. Res., 57, 67–75. · DOI
  88. Lee, L., Sudentas, P., Donohue, B., Asrican, K., Worku, A., Walker, V., Sun, Y., Schmidt, K., Albert, M.S., El-Hashemite, N. et al. (2005) Efficacy of a rapamycin analog (CCI-779) and IFN-gamma in tuberous sclerosis mouse models. Genes Chromosomes Cancer, 42, 213–227. · DOI

Cited by

Sorted by citations

Metadata

Authors
Kwiatkowski, D. J., & Manning, B. D.
Venue
Human Molecular Genetics
Publisher
Oxford University Press (OUP)
Published
2005-10-15
Volume
14
Issue
suppl_2
Pages
R251-R258
ISSN
  • 1460-2083
  • 0964-6906
DOI
10.1093/hmg/ddi260
Cited by
332
References
6
Language
en

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review